Last updated on July 2020

An Open-label Phase II Study of AZD4635 in Patients With Prostate Cancer


Brief description of study

This is an open-label Phase II modular study in patients with prostate cancer which will assess safety, efficacy, and tolerability of AZD4635 in combination with other therapeutic agents in different treatment arms (referred to as modules).

Combinations to be studied include: 1) Module 1: AZD4635 plus durvalumab; 2) Module 2: AZD4635 plus oleclumab.

The protocol may be amended to include other combinations.

Detailed Study Description

This is an open-label Phase II modular study in patients with prostate cancer which will assess safety, efficacy, and tolerability of AZD4635 in combination with other therapeutic agents in different treatment arm (referred to as modules).

Combinations to be studied include: 1) Module 1: AZD4635 plus durvalumab; 2) Module 2: AZD4635 plus oleclumab. The protocol may be amended to include other combinations.

All patients will be allocated into a module using an Interactive Web Response System (IWRS). Randomization will occur when patients meet eligibility criteria for two or more modules that are currently recruiting. If patients only meet the criteria for only one currently recruiting module, they will be allocated to that module without randomization taking place.

The primary objective of the clinical study is to evaluate the efficacy of each combination therapy by: 1) assessing the objective response rate (ORR) of patients with measurable disease [response will be determined by Response Evaluation Criteria in Solid Tumours (RECIST 1.1)]; 2) assessing the PSA confirmed response rate of each combination therapy [PSA confirmed response rate is defined as the proportion of participants with a reduction in the PSA level of 50% measured from baseline to the lowest post-baseline PSA result measured twice, at least 3 weeks apart by the Prostate Cancer Working Group 3 criteria PCWG3).

The primary safety endpoints include assessment of adverse events and serious adverse events, physical examinations, vital signs, and collection of clinical chemistry/hematology parameters

In Modules 1 and 2 there will be approximately 30 evaluable patients in each module, and at least 20 patients will have RECIST measurable disease at baseline. If any of the required patients for PSA and/or ORR are not evaluable for PSA response or tumor response, respectively, they may be replaced at the sponsor's discretion.

Clinical Study Identifier: NCT04089553

Find a site near you

Start Over

Research Site

Sarasota, FL United States
5.43miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.